Ronald Matteotti

Lead Next Generation Pancreas Cancer Working Group (Nextgen-pdac) @Bristol Myers Squibb

Trenton, NJ, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Aug 2021 — Present

Lead Next Generation Pancreas Cancer Working Group (Nextgen-pdac) @Bristol Myers Squibb

View department →

Princeton, NJ, US

EDUCATION

2020 — 2020

Haslam College of Business at the University of Tennessee

PE MBA

2009 — 2010

Fox Chase Cancer Center

Surgical oncologist

1988 — 1994

Universität Basel

Doctor of Medicine (M.D.)

1978 — 1988

Gymnasium Vaduz, Principality of Liechtenstein

Matura

2020 — 2021

Wharton Online

Entrepreneurship Acceleration Program

1995 — 2000

Swiss Medical Federation - FMH

General Surgery Residency Program

2003 — 2004

Mount Sinai School of Medicine of New York University

Research Fellowship, Minimally Invasive Surgery & Bariatrics

2006 — 2009

University Hospital of Cleveland

Surgeon

1973 — 1978

Primarschule Balzers, Principality of Liechtenstein

Primarschueler

2021 — 2022

Wharton Online

Digital marketing - Fundamentals of Digital Marketing, Social Media, and e-Commerce

2021 — 2022

Wharton Online

Digital Marketing - Marketing Analytics: Data Tools and Techniques

2021 — 2022

Wharton Online

Digital Marketing - Selling Ideas: How to Influence Others and Get Your Message to Catch On

ABOUT RONALD MATTEOTTI

Accomplished and globally recognized pharmaceutical executive with over 20 years of experience in healthcare and more than 5 years in Global Medical Affairs, spanning oncology, immuno-oncology, and the medical device industry. A triple board-certified physician with deep therapeutic expertise in pancreas and liver cancers, backed by an MBA and a Chief Medical Officer (CMO) certification, bringing advanced strategic, operational, and leadership capabilities to global roles. Proven success in clinical drug development as a clinical trial physician, including leadership in pivotal global Phase trials such as CheckMate 8HW (MSI-H colorectal cancer) and CheckMate 9DW (first-line hepatocellular carcinoma). Recognized as a digital health and omnichannel engagement expert, I have designed and led a comprehensive global digital health strategy for one of the top five pharmaceutical companies, aligning innovation, data integration, and customer engagement across markets. Known for leading cross-functional global teams in medical affairs, R&D, commercial, regulatory, and market access functions in complex matrixed environments. Strong regional execution track record across the US, EU5, and APAC, focusing on evidence generation, HEOR, scientific communication, and KOL engagement. Fluent in English, German, and French, with conversational Italian. Committed to delivering patient-centered innovation at scale through visionary leadership, scientific integrity, and digital transformation. Core competencies: • Global Medical Affairs Strategy & Leadership • Digital Health & Omnichannel Innovation • Oncology Drug Development • Pancreas & Liver Cancer Expertise • Clinical Trial Design & Execution (Phase • Launch Leadership (CheckMate 8HW, 9DW) • Evidence Generation & RWE Integration • Scientific & Medical Communications • KOL & Stakeholder Engagement • HEOR & Market Access Alignment • Global Market Experience: US, EU5, APAC • MBA & CMO-Credentialed Executive Leadership

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Ronald Matteotti — Lead Next Generation Pancreas Cancer Working Group (Nextgen-pdac) at Bristol Myers Squibb in Trenton, NJ, US | Unifers